Clinical trial NCT02977065: To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
Official title: Multicenter, Parallel-group, Double-blind, Randomized, Active-controlled, Dose-ranging Study to Assess the Safety, Efficacy, and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors, in Subjects With Dyslipidemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dyslipidemias
Keywords: Dyslipidemia
CETP Inhibitors
Hyperlipidemia
Lead sponsor: Chong Kun Dang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2016-11-30
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or rosuvastatin in subjects with dyslipidemia.

Detailed description: The purpose of this study is to assess the safety, efficacy, and tolerability of CKD-519, administered with HMG-CoA reductase inhibitors in subjects with dyslipidemia

Eligibility criteria: Inclusion Criteria:

1. Age 18 to 80 years.
2. Dyslipidemia with LDL-C

   * At screening if untreated: 100 to 190 mg/dL
   * At screening if treated with statins or other lipid-lowering drugs: 100 to 170 mg/dL
   * At start of double-blind treatment: 100 to 190 mg/dL.
3. HDL-C \<45 mg/dL (males) or \<50 mg/dL (females).
4. Fasting TG \<400 mg/dL.
5. Presence of the following conditions is permitted but not mandatory, at the discretion of the investigator:

   * Treated and stable coronary heart disease without acute events in the past 3 months and stable, state-of-the-art medication.
   * Treated and stable carotid artery disease or peripheral arterial disease on stable, standard medication for the past 3 months
   * Treated and stable Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤9.5%.
6. Willing and able to sign the informed consent form (ICF).

Exclusion Criteria:

1. Chronic heart failure as defined by New York Heart Association classes III and IV.
2. Uncontrolled cardiac arrhythmias.
3. Myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, or unstable angina in past 3 months before Visit 1.
4. Stroke or transient ischemic attack within 3 months before Visit 1.
5. Uncontrolled hypertension.
6. Clinically significant laboratory abnormalities

   * Aspartate aminotransferase or alanine aminotransferase \>2 times upper limit of normal range
   * Bilirubin \>1.5 times upper limit of normal range
   * Creatine kinase \>2 times upper limit of normal range.
7. Any active nephropathy or estimated glomerular filtration rate \<60 mL/min/1.73m2 or on kidney dialysis.
8. Poorly controlled (thyroid-stimulating hormone \[TSH\] \>2 times upper limit of normal) hyperthyroidism.
9. Homozygous familial hypercholesterolemia.
10. Intolerance or hypersensitivity to atorvastatin or rosuvastatin.
11. Prior treatment with any CETP inhibitor.
12. Positive for human immunodeficiency virus (HIV) positive, hepatitis B or hepatitis C.

Primary outcomes:
measure: Percentage change from baseline (Visit 3) in LDL-C
timeFrame: at Week 4
Secondary outcomes:
measure: Percentage change from baseline in HDL-C
timeFrame: at Weeks 2 and Week 4
measure: Percentage change from baseline in concentration of HDL particles (HDL-P)
timeFrame: at Weeks 2 and 4
measure: Change from baseline in size of HDL particles (HDL-P)
timeFrame: at Weeks 2 and 4
measure: Percentage change from baseline in LDL-C
timeFrame: at Week 2
measure: Change in concentration from baseline in LDL-C
timeFrame: at Weeks 2 and 4
measure: Change in concentration from baseline in HDL-C
timeFrame: at Weeks 2 and 4
measure: Percentage change from baseline in total cholesterol, TG, and non-HDL-C
timeFrame: at Weeks 2 and 4
measure: Change in concentration from baseline in total cholesterol, TG, and non-HDL-C
timeFrame: at Weeks 2 and 4
measure: Percentage change from baseline in apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), and apolipoprotein E (Apo E)
timeFrame: at Weeks 2 and 4
measure: Change in concentration from baseline in Apo B, Apo A1, and Apo E
timeFrame: at Weeks 2 and 4
measure: Percentage change from baseline in lipoprotein(a) (Lp-a)
timeFrame: at Weeks 2 and 4
measure: Change in concentration from baseline in Lp-a
timeFrame: at Weeks 2 and 4
measure: Change in concentration from baseline in high-sensitivity C-reactive protein at
timeFrame: at Weeks 2 and 4
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: Not provided
Study officials:
affiliation: Chong Kun Dang Pharm.
name: Kyung-Mi Park, PhD
role: STUDY_DIRECTOR
References: